Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2017-A02391-52 | Other Identifier | ID-RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Spondylarthropathies (SpA) are among the most common chronic inflammatory rheumatisms in adults, responsible for a muscular loss or sarcopenia which can be very disabling, not much documented in the literature, and not yet studied in France. In addition, sarcopenia is associated with decreased physical activity and increased risk of falls and fractures. A better characterization of the determinants of this muscular loss will allow to better detect and take care of it.
The aim is to conduct the first French study on the prevalence and severity of sarcopenia in patients with spondyloarthropathies and to study the variables that may be associated with it. Finally, we propose to evaluate obesity related to sarcopenia in these patients and compare them to cases matched for age and sex (from OFELY / STRAMBO cohorts, Lyon, FRANCE).
This is a prospective interventional and monocentric study with minimal risks and constraints: patients will be included for one day for an evaluation of their sarcopenia by measuring their muscle strength, physical performance and body composition and recording of their socio-demographic and disease characteristics.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with SpA | Experimental | Patients included in this single group study will have 3 interventions to assess the severity of muscle loss :
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dynamometry exam | Other | Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength |
|
| Measure | Description | Time Frame |
|---|---|---|
| Muscular strength | Muscular strength is the first outcome to evaluate sarcopenia | At day 1 |
| Walking speed | Walking speed is a physical performance outcome, that is the second outcome to evaluate sarcopenia | At day 1 |
| Muscular mass | Muscular mass is the third outcome to evaluate sarcopenia and will be assessed using DXA | Up to 4 month after inclusion |
| Measure | Description | Time Frame |
|---|---|---|
| Alcohol consumption | At day 1 | |
| Tobacco consumption | At day 1 | |
| Time of sport practice per month |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Service de Rhumatologie - Hôpital Edouard Herriot | Lyon | 69003 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36944706 | Result | Merle B, Cottard M, Sornay-Rendu E, Szulc P, Chapurlat R. Spondyloarthritis and Sarcopenia: Prevalence of Probable Sarcopenia and its Impact on Disease Burden: The Saspar Study. Calcif Tissue Int. 2023 Jun;112(6):647-655. doi: 10.1007/s00223-023-01074-3. Epub 2023 Mar 21. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D025242 | Spondylarthropathies |
| D055948 | Sarcopenia |
| ID | Term |
|---|---|
| D025241 | Spondylarthritis |
| D013166 | Spondylitis |
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Walking test | Other | A 4 metres walking test will be performed to assess patient's walking speed |
|
| DXA measurement | Radiation | DXA measurement will be performed to assess patient's body composition |
|
| SARQOL questionnaire | Other | Patient's quality of life will be assessed thanks to the SARQOL questionnaire |
|
| Life habits Questionnaire | Behavioral | Life habits Questionnaire |
|
Number of hours of sport practice per month is the first outcome to evaluate patient's global physical activity.
| At day 1 |
| Physical activity rate in work | Physical activity rate in work can be light, medium, high or not applicable if the patient does not work ; it is the second outcome to evaluate patient's physical global activity. | At day 1 |
| Average walking time in a week | Average walking time in a week is the third outcome to evaluate patient's physical global activity. | At day 1 |
| Score at the SARQOL questionnaire | Quality of life will be assessed thanks to the SARQOL questionnaire (score between 0 and 100) | At day 1 |
| D009140 |
| Musculoskeletal Diseases |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |